Anxiolytic peptides backed by research - selank, semax, DSIP and calming compounds with mechanisms and dosing.
A synthetic analog of tuftsin with Pro-Gly-Pro for stability. Developed at the Russian Academy of Sciences with anxiolytic and nootropic properties without sedation or addiction.
Dose: 250-750 mcg per spray dose | Route: Intranasal spray
A synthetic peptide from ACTH(4-10) with Pro-Gly-Pro stabilization. Approved in Russia for stroke and cognitive disorders. Enhances attention, memory, and neuroplasticity.
Dose: 200-600 mcg per dose | Route: Intranasal drops/spray
A nonapeptide discovered in 1977 that modulates sleep architecture by promoting delta wave (deep sleep) patterns and normalizing circadian disruptions.
Dose: 100-300 mcg | Route: Subcutaneous injection
The rate-limiting precursor to glutathione synthesis. NAC replenishes intracellular GSH, protects the liver from oxidative damage, breaks down mucus, and chelates heavy metals. Also researched for OCD
Dose: 600-1800 mg | Route: Oral capsule or IV (hospital)
An angiotensin IV analog reported 10 million times more potent than BDNF at enhancing synaptic connectivity. Promotes synaptogenesis and spinogenesis.
Dose: 10-20 mg (oral) or 2-5 mg (SubQ) | Route: Oral or Subcutaneous
A small molecule stimulating hippocampal neurogenesis. Developed for MDD, it increases hippocampal volume measurable by MRI and improves cognition independent of mood effects.
Dose: 40-80 mg | Route: Oral
A multi-peptide preparation from porcine brain containing neurotrophic factors. Approved in 40+ countries for stroke and dementia, providing a cocktail of low-MW neuropeptides.
Dose: 5-30 mL | Route: Intramuscular or IV
Read full Cerebrolysin guide →
A CNTF-derived peptide promoting neurogenesis that crosses BBB. Stimulates hippocampal neurogenesis without CNTF appetite-suppressing effects.
Dose: 50-100 mcg/kg | Route: Intranasal or Subcutaneous
A peptide from the FG loop of neural cell adhesion molecule (NCAM). Enhances synaptic plasticity, memory, and neurotrophic effects through FGFR activation.
Dose: 1-5 mg/kg (research) | Route: Subcutaneous
A positive allosteric modulator of AMPA receptors enhancing glutamatergic transmission. Effects last days after single dose.
Dose: 10-30 mg | Route: Oral
A dipeptide-derived nootropic ~1000x more potent than piracetam. Enhances memory, focus, and provides neuroprotection through BDNF/NGF upregulation and AMPA/NMDA modulation.
Dose: 10-30 mg | Route: Oral or Sublingual
An experimental peptide analog enhancing GABAergic sleep signaling without benzodiazepine-like tolerance and dependence. Selectively targets sleep-active VLPO neurons.
Dose: 200-500 mcg | Route: Subcutaneous